The world’s first Chinese government approved inhaled vaccine Against COVID-19, vaccine manufacturer Cansino Biologics announced Sunday.
The vaccine, called Convidecia Air, changes the liquid form of the vaccine into an aerosol using a nebulizer. The vaccine can then be inhaled orally using a nebulizer. Cansino said in a statement that the needle-free vaccine “can effectively induce a comprehensive immune protection response to SARS-2 virus after just one breath.”.
Science appears to support Cancino’s claims.
In July, Chinese scholars published Pre-print study It was found that people who received a booster dose of inhaled Cansino vaccine after two doses of the inactivated vaccine from the Chinese company Sinovac developed more antibodies than people who received three shots of Sinovac. Four weeks after receiving the inhaled booster, 92.5% of subjects had developed omicron-neutralizing antibodies.
Those who received three doses of the Sinovac dose showed no omicron neutralizing antibodies, either four weeks or six months after receiving a booster dose.
Cansino’s share price jumped 8% in Hong Kong on Monday.
Pay US Vaccine
Leading scientists such as Eric Topol, executive vice president of Scripps Research, have called on the US government to accelerate efforts to develop inhaled and nasal spray vaccines, believing that they may target omicron infections better than injected vaccines.
“Once [Omicron] It enters through the nasal mucosa, or oral mucosa, the upper airway. This game is over [for] Topol said recently in a podcast With former US President Joe Biden’s COVID-19 response coordinator Andy Slavett. “The best way… to stimulate upper airway mucosal immunity is with either nasal or oral vaccinations.
The Cansino booster vaccine is a single-injection inhaled version of the COVID-19 adenovirus vaccine developed by Cansino. in partnership With the Chinese Academy of Military Medical Sciences run by the military. The initial vaccine proved 66% effective in preventing infection, and 92% effective against severe disease in early clinical trials. It has been green lighted for use as a booster and initial vaccine dose by the Chinese government, the World Health Organization and many other countries.
But Cancino’s hit was not as widely distributed as initially expected. The company led the race to develop a COVID-19 vaccine early in the pandemic, ahead of foreign companies such as Pfizer And the modern And Chinese companies Sinovac and SinopharmBut then it was late in approval and distribution. Even with Monday’s boost, Cansino’s share price is down 87% since the end of 2020, when vaccine makers first introduced COVID shots to the market.
Over the weekend, the Chinese government approved a new protein dose – from local company Livezone Pharma – for use as a booster.
It’s unclear to what extent the Cansino or Levzone vaccines will be distributed or how useful the new vaccines will be in China’s fight against COVID-19, given that the market appears largely saturated.
China has already distributed over 3.4 billion doses to its citizens, providing two or more doses for 89.7% of its population. By comparison, 66.8% of people in the United States have gotten two or more COVID-19 shots.
Despite the successful vaccination campaign in China, as well as mounting popular unrest and economic pressures, the government has also not deviated from a strict zero-coronavirus policy and continues to use strict lockdowns, border restrictions and mass testing measures to eliminate all cases of the virus. . This means that Chinese citizens may feel little incentive to seek a new vaccine, given that the Chinese government has not provided a specific timeline for moving to a ‘living with COVID’ strategy like almost any other country in the world.
Chengdu, a city of 21 million in central China, has implemented a citywide stay-at-home since last Thursday amid a local surge of a few hundred cases. In total, there are 65 million people in China living under partial or complete lockdown, according to Chinese outlets Caixin.
Sign up for Wealth Features Email list so you don’t miss out on our biggest features, exclusive interviews and investigations.